Cite
HARVARD Citation
Hodi, F. et al. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet oncology. 19 (11), pp. 1480-1492. [Online].